Pertussis toxoid and acellular pertussis antigens (aP)

Pertussis toxoid and acellular pertussis antigens are the immunogenic components derived from the bacterium Bordetella pertussis used in modern vaccines to prevent whooping cough. The pertussis toxoid is a chemically or genetically inactivated version of the pertussis toxin, the primary virulence factor responsible for the systemic symptoms and lymphocytosis associated with the infection. Acellular antigens typically include purified surface proteins such as filamentous hemagglutinin (FHA), pertactin (PRN), and fimbriae (FIM), which are essential for bacterial adhesion to the ciliated respiratory epithelium. When administered, these antigens prime the host's immune system to recognize and neutralize the pathogen and its toxins, providing protective immunity (CDC, 2023). These components were developed to replace whole-cell pertussis vaccines to significantly reduce the incidence of local and systemic adverse effects. They are currently administered as part of combination vaccines like DTaP for infants and children, and Tdap for adolescents, adults, and pregnant women. While highly effective at preventing severe disease, immunity derived from these acellular antigens tends to wane more rapidly than whole-cell vaccines, necessitating periodic booster doses to maintain population-level protection (WHO, 2015).

Other names

Acellular pertussis vaccine componentsPertussis toxin (inactivated)PTFilamentous hemagglutinin (FHA)Pertactin (PRN)Fimbriae types 2 and 3 (FIM2/3)Bordetella pertussis antigens

These antigens induce active immunity by stimulating the production of specific antibodies and memory B and T cells. The pertussis toxoid triggers neutralizing antibodies that block the systemic effects of the pertussis toxin, while acellular components like filamentous hemagglutinin, pertactin, and fimbriae induce antibodies that inhibit the attachment of Bordetella pertussis to the respiratory epithelium (StatPearls, 2023; DrugBank, 2024).